
The first vaccine designed to protect infants against respiratory syncytial virus (RSV) by vaccinating their mothers during pregnancy has been backed by a panel of advisers to the U.S. Food and Drug Administration. On Thursday the independent committee of experts voted unanimously that the Pfizer-made vaccine was effective, and 10-4 that there was adequate data on safety to move the vaccine to approval, the Associated Press reported. The shot would be given to pregnant women at 24 to 36 weeks gestation. This should stimulate the production of maternal antibodies to RSV that would then pass through the placenta to the fetus. “Before the pandemic, RSV was the No. 1 cause of infant hospitalization in the United States, so this is a big deal,” Dr. Ofer Levy, director of the precision vaccines program at Boston Children’s Hospital, told NBC News. Levy is a temporary voting member of the panel, but not one who voted on this vaccine. The FDA will still need to approve the vaccine, a process that could take months. The agency is not obligated to follow its advisers’ recommendations, but it usually does. The Pfizer-made vaccine would only be the second one ever approved in the United States for RSV. A vaccine made by pharmaceutical company GSK was approved for adults ages 60 and up earlier this month. However, 11 RSV vaccines for… read on > read on >